Christopher Richard Anzalone, Chief Executive Officer at ARROWHEAD PHARMACEUTICALS, INC. (ARWR), sold 367,130 shares at $67.87 ($24.6M) on 2025-12-16, disclosed to the SEC on 2025-12-16.
Seasonal sale ($24.6M) by Chief Executive Officer — this insider has traded ARWR in December in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $68.67 | 100,532 | $6.9M | 28.1% |
| 2 | $68.67 | 100,532 | $6.9M | 28.1% |
| 3 | $69.28 | 21,321 | $1.5M | 6.0% |
| 4 | $69.28 | 21,321 | $1.5M | 6.0% |
| 5 | $69.96 | 8,147 | $570K | 2.3% |
| 6 | $69.96 | 8,147 |
| $570K |
| 2.3% |
| 7 | $60.51 | 8,416 | $509K | 2.1% |
| 8 | $60.51 | 8,416 | $509K | 2.1% |
| 9 | $61.25 | 10,963 | $671K | 2.7% |
| 10 | $61.25 | 10,963 | $671K | 2.7% |
| 11 | $62.12 | 14,095 | $876K | 3.6% |
| 12 | $62.12 | 14,095 | $876K | 3.6% |
| 13 | $62.94 | 8,476 | $533K | 2.2% |
| 14 | $62.94 | 8,476 | $533K | 2.2% |
| 15 | $64.29 | 6,661 | $428K | 1.7% |
| 16 | $64.29 | 6,661 | $428K | 1.7% |
| 17 | $64.96 | 1,000 | $65K | 0.3% |
| 18 | $64.96 | 1,000 | $65K | 0.3% |
| 19 | $65.77 | 1,300 | $86K | 0.3% |
| 20 | $66.77 | 166 | $11K | 0.0% |
| 21 | $67.87 | 3,221 | $219K | 0.9% |
| 22 | $67.87 | 3,221 | $219K | 0.9% |
| Total | $67.01 avg | 367,130 | $24.6M | 100% |
| Filing → |
| ARWR | SELL | 2025-12-23 | $3.5M | — | Filing → |
| ARWR | SELL | 2025-12-19 | $10.9M | — | Filing → |
| ARWR | SELL | 2025-04-11 | $1.9M | — | Filing → |